EUVIMEDEUVIMED entdecken
Multizentrische Studie

Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

Reika Yamauchi, Takanori Ito, Sachiyo Yoshio iD, Takafumi Yamamoto, Kazuyuki Mizuno, Masatoshi Ishigami, Hiroki Kawashima, Satoshi Yasuda, Shigeo Shimose, Hideki Iwamoto, Taiji Yamazoe, Taizo Mori und 4 weitere

Journal of Gastroenterology · 2023

DOI: 10.1007/s00535-023-01985-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology, 2023. Verfasst von Reika Yamauchi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichi…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: AMED, Grants-in-Aid for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Combination therapy with anti-programmed death-ligand 1 and anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for un-resectable hepatocellular carcinoma (uHCC). We aimed to identify predictive circulating biomarkers for the outcome/response of the combination therapy in uHCC patients. METHODS: This prospective multicenter study enrolled 70 patients with uHCC who received atezolizumab and bevacizumab (Atez/Bev). We evaluated 47 circulating proteins in sera before and after 1 and 6 weeks of Atez/Bev therapy by multiplex bead-based immunoassay and ELISA. As controls, we analyzed the sera from 62 uHCC patients before treatment of lenvatinib (LEN) and healthy volunteers (HVs). RESULTS: The disease control rate was 77.1%. Median progression-free survival (PFS) was 5.7 months (95% confidence interval [CI] = 3.8-9.5). The pretreatment levels of osteopontin (OPN), angiopoietin-2, VEGF, S100-calcium-binding protein A8/S100-calcium-binding protein A9, soluble programmed cell death-1, soluble CD163, and 14 cytokines/chemokines were higher in patients with uHCC than in HVs. Among these, pretreatment OPN levels were higher in PD group than in non-PD group for Atez/Bev. The PD rate was higher in high OPN group than in low OPN group. Multivariate analysis identified high pretreatment OPN and high α-fetoprotein levels as independent predictors of PD. In the sub-analysis of Child-Pugh class A patients, PFS was also shorter in the high OPN group than in the low OPN group. Pretreatment OPN level was not associated with treatment response for LEN. CONCLUSION: High serum OPN levels were associated with poor response to Atez/Bev in patients with uHCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansBevacizumabOsteopontinVascular Endothelial Growth Factor AProspective StudiesCalcium-Binding ProteinsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Angiopoietin-2Immune checkpoint inhibitorMacrophagePD-L1VEGF

Substanzen

BevacizumabOsteopontinVascular Endothelial Growth Factor ACalcium-Binding ProteinsatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, 272-8516, Japan.
  • Division of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, 272-8516, Japan. sachiyo@hospk.ncgm.go.jp.
  • Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.

ORCID-Profile: Sachiyo Yoshio

Förderung

  • AMED
  • Grants-in-Aid for Scientific Research

Zitieren

APA

Yamauchi, R., Ito, T., Yoshio, S., Yamamoto, T., Mizuno, K., Ishigami, M., Kawashima, H., Yasuda, S., Shimose, S., Iwamoto, H., Yamazoe, T., Mori, T., Kakazu, E., Kawaguchi, T., Toyoda, H., & Kanto, T. (2023). Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. Journal of Gastroenterology. https://doi.org/10.1007/s00535-023-01985-w

Vancouver

Yamauchi R, Ito T, Yoshio S, Yamamoto T, Mizuno K, Ishigami M, et al. Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. Journal of Gastroenterology. 2023. doi:10.1007/s00535-023-01985-w

BibTeX
@article{Yamauchi2023,
  author = {Yamauchi, Reika and Ito, Takanori and Yoshio, Sachiyo and Yamamoto, Takafumi and Mizuno, Kazuyuki and Ishigami, Masatoshi and Kawashima, Hiroki and Yasuda, Satoshi and Shimose, Shigeo and Iwamoto, Hideki and Yamazoe, Taiji and Mori, Taizo and Kakazu, Eiji and Kawaguchi, Takumi and Toyoda, Hidenori and Kanto, Tatsuya},
  title = {Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma},
  journal = {Journal of Gastroenterology},
  year = {2023},
  doi = {10.1007/s00535-023-01985-w}
}
Kostenlos starten →